Chronic fatigue syndrome, also known as myalgic encephalomyelitis (ME/CFS), is a debilitating condition that has puzzled researchers for years. However, a recent groundbreaking study has shed light on the genetic factors that contribute to the onset of ME/CFS. This study, conducted by a team led by Steve Gardner at Precision Life in Oxford, is the largest of its kind to date and has identified more than 250 genes that play a role in ME/CFS – six times the number previously identified.
ME/CFS is characterized by symptoms such as post-exertional malaise, where even minor physical activity can lead to prolonged exhaustion. While the condition is often triggered by an infection, it remains unclear why some individuals develop ME/CFS after such an infection while others do not.
To delve deeper into the genetic basis of ME/CFS, Gardner’s team analyzed genomic data from over 10,500 individuals diagnosed with the condition. By comparing this data with genetic information from individuals without ME/CFS, the researchers identified specific genetic variants, known as single nucleotide polymorphisms (SNPs), that are associated with an increased risk of developing ME/CFS.
Rather than focusing on individual SNPs, the researchers looked at groups of SNPs that work together to influence the risk of ME/CFS. They identified 22,411 groups composed of 7555 SNPs, with individuals having more of these groups being at higher risk of developing the condition. Additionally, the team mapped these SNPs to 2311 genes, pinpointing 259 “core” genes that are strongly linked to ME/CFS.
This new understanding of the genetic underpinnings of ME/CFS opens up avenues for developing targeted treatments that address the root causes of the condition. Currently, there are no specific medications for ME/CFS, and patients are often prescribed painkillers or antidepressants to manage symptoms. By identifying key genetic factors, researchers hope to develop more effective treatments that could benefit a larger number of patients.
The study also compared the genetic findings of ME/CFS with those of long covid, another condition triggered by infection that shares similarities with ME/CFS. Interestingly, the researchers found that about 42% of the genes identified in long covid were also linked to ME/CFS, suggesting a partial overlap between the two conditions. Further research is needed to explore the relationship between these conditions and uncover potential shared genetic pathways.
Overall, this study represents a significant step forward in understanding ME/CFS and paves the way for more targeted and effective treatments for this debilitating condition. As researchers continue to unravel the genetic complexities of ME/CFS, there is hope for better management and care for individuals living with this challenging condition. Altmann, a leading research institute in the field of chronic fatigue syndrome (CFS) and long covid, is taking a groundbreaking approach to understanding these complex conditions. They are actively recruiting individuals who have been diagnosed with both ME/CFS and long covid, with the goal of conducting high-tech, high-resolution analyses to uncover the underlying mechanisms of these conditions.
One of the key areas of focus for Altmann is the participants’ immune systems. Research has shown that immune dysfunction plays a significant role in both ME/CFS and long covid, and by conducting in-depth analyses of the immune systems of individuals with these conditions, Altmann hopes to gain valuable insights into how these conditions develop and manifest.
In addition to immune system analysis, Altmann is also investigating the presence of latent viruses in the bodies of participants. Viral infections have been linked to both ME/CFS and long covid, and by identifying and studying these latent viruses, researchers at Altmann hope to better understand the relationship between viral infections and the onset of these conditions.
Furthermore, Altmann is exploring the role of gut microbiomes in ME/CFS and long covid. The gut microbiome has been increasingly recognized as a key player in overall health, and emerging research suggests that alterations in the gut microbiome may contribute to the development of chronic conditions such as ME/CFS and long covid. By analyzing the gut microbiomes of participants, Altmann aims to uncover potential links between gut health and these conditions.
By conducting comprehensive analyses of immune systems, latent viruses, and gut microbiomes in individuals with ME/CFS and long covid, Altmann hopes to gain a deeper understanding of the underlying mechanisms of these conditions. This personalized approach to research will allow researchers to identify factors that may be driving these conditions in individual patients, paving the way for targeted treatment strategies.
Dr. Altmann emphasizes the importance of understanding the mechanisms behind ME/CFS and long covid on an individual level. By uncovering how these conditions vary from person to person, researchers can develop more personalized and effective treatment approaches. Through their cutting-edge research, Altmann is working towards a future where ME/CFS and long covid can be targeted directly, leading to improved outcomes for individuals living with these challenging conditions.
